Press release
Sarcoidosis Treatment Market 2032: EMA, PDMA, FDA Approval, Clinical Trials, Medication, NICE Approval, Prevalence, Revenue, Statistics and Companies by DelveInsight
Sarcoidosis Treatment Market
The Sarcoidosis market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted Sarcoidosis market size from 2019 to 2032. It also evaluates the current Sarcoidosis treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Sarcoidosis market.
Discover which therapies are expected to grab the Sarcoidosis Market Share @ Sarcoidosis Market Outlook - https://www.delveinsight.com/sample-request/sarcoidosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Key Takeaways from the Sarcoidosis Market Report
• In March 2025, aTyr Pharma, Inc. (Nasdaq: ATYR) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced the outcome of a fourth, pre-planned interim safety analysis conducted by an independent data and safety monitoring board (DSMB) for the ongoing Phase 3 EFZO-FITTM study of the Company's lead therapeutic candidate, efzofitimod, in patients with pulmonary sarcoidosis. The DSMB recommended that the study continue without any modifications.
• In March 2025, ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced U.S. Food and Drug Administration (FDA) approval of Purified Cortrophin® Gel (repository corticotropin injection USP) (Cortrophin Gel) in a prefilled syringe format. This new presentation will be available in 40 USP units/0.5 mL and 80 USP units/mL single-dose options through Cortrophin Gel's established specialty pharmacy network. The prefilled syringe reduces administration steps for patients using Cortrophin Gel, which remains available in 5 mL and 1 mL vials.
• June 2024:- aTyr Pharma Inc.- A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis. This is a multicenter, randomized, double-blind, placebo-controlled, study comparing the efficacy and safety of intravenous (IV) efzofitimod 3 mg/kg and 5 mg/kg versus placebo after 48 weeks of treatment. This study will enroll adults with histologically confirmed pulmonary sarcoidosis receiving stable treatment with oral corticosteroid (OCS), with or without immunosuppressant therapy.
• May 2024:- Xentria Inc.- A Seamless, Phase 1b/2 Multiple Ascending Dose/Proof of Concept Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis With or Without Extrapulmonary Manifestations. A phase 1b/2 study of XTMAB-16 in patients with pulmonary sarcoidosis
• May 2024:- University of Florida- An Open-Label Study of Inhaled Treprostinil in Sarcoidosis Patients With Pulmonary Hypertension and Interstitial Lung Disease (SAPPHIRE). This study aims to evaluate the efficacy and safety of inhaled treprostinil in subjects with sarcoidosis-associated interstitial lung disease and pulmonary hypertension.
• The Sarcoidosis market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• The leading Sarcoidosis Companies such as Pfizer (NYSE: PFE), United Therapeutics (NASDAQ: UTHR), Xentria, Inc. (Private), aTyr Pharma, Inc. (NASDAQ: LIFE), Kyorin Pharmaceutical Co., Ltd. (TSE: 4569), Novartis (SWX: NOVN), Kinevant Sciences GmbH (Private), Foresee Pharmaceuticals (TPEx: 6576), AI Therapeutics (Private), Molecure (WSE: MOC), and others.
• Promising Sarcoidosis Therapies such as Abrocitinib, Inhaled Treprostinil, XTMAB-16, Efzofitimod, CMK389, Namilumab, FP-020, LAM001, OATD-01, and others.
Sarcoidosis Epidemiology Segmentation
• Total Prevalence
• Prevalent Cases of Sarcoidosis by severity
• Gender-specific Prevalence
• Diagnosed Cases of Episodic and Chronic
Download the report to understand which factors are driving Sarcoidosis Epidemiology trends @ Sarcoidosis Epidemiological Insights - https://www.delveinsight.com/sample-request/sarcoidosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Sarcoidosis Therapies and Key Companies
• Abrocitinib: Pfizer
• Inhaled Treprostinil: United Therapeutics
• XTMAB-16: Xentria, Inc.
• Efzofitimod: aTyr Pharma, Inc./Kyorin Pharmaceutical Co., Ltd
• CMK389: Novartis
• Namilumab: Kinevant Sciences GmbH
• FP-020: Foresee Pharmaceuticals
• LAM001: AI Therapeutics
• OATD-01: Molecure
Sarcoidosis Market Drivers
Strategic alliances between the Pharmaceutical companies and universities, extensive research undertaking and funding are some of the important factors that are fueling the Sarcoidosis Market.
Sarcoidosis Market Barriers
However, side-effects associated with the treatment of Sarcoidosis, lack of awareness among people in developing countries and other factors are creating obstacles in the Sarcoidosis Market growth.
To know more about Sarcoidosis treatment, visit @ Sarcoidosis Medications and Companies- https://www.delveinsight.com/sample-request/sarcoidosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Sarcoidosis Drugs Market
The Sarcoidosis Drugs Market is expected to witness substantial growth in the coming years as more targeted therapies receive regulatory approval and enter clinical practice. Additionally, ongoing research efforts aimed at better understanding the molecular mechanisms underlying Sarcoidosis signaling in Sarcoidosis are likely to uncover new therapeutic targets and further expand treatment options for patients.
Sarcoidosis Treatment Market Landscape
The Sarcoidosis treatment market landscape has witnessed significant advancements over the past years, with targeted therapies playing a crucial role in improving outcomes for patients. Among these targeted therapies, the emergence of Sarcoidosis has garnered attention in the medical community, presenting both challenges and opportunities in treatment strategies.
Sarcoidosis Market Outlook
The report's outlook on the Sarcoidosis market aids in developing a comprehensive understanding of historical, current, and projected trends. This is achieved by examining the influence of existing Sarcoidosis therapies, unmet needs, as well as drivers, barriers, and the demand for advanced technology. This section provides detailed insights into the trends of each marketed Sarcoidosis drug and late-stage pipeline therapy. It assesses their impact based on various factors such as annual therapy costs, inclusion/exclusion criteria, mechanism of action, compliance rates, market demand, patient population growth, covered patient segments, anticipated launch year, competition with other therapies, brand value, and input from key opinion leaders. The analyzed Sarcoidosis market data are presented concisely through relevant tables and graphs to offer a clear overview of the market dynamics.
Know more about the therapies and drugs @ Sarcoidosis Clinical Trials and FDA Approvals- https://www.delveinsight.com/sample-request/sarcoidosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Sarcoidosis Drugs Uptake
The drug chapter of the Sarcoidosis report provides a comprehensive analysis of both marketed drugs and late-stage pipeline drugs for this condition. It delves into the details of clinical trials, pharmacological actions, agreements, collaborations, approvals, patents, and advantages, and disadvantages of each drug, as well as the latest news and press releases related to Sarcoidosis.
Scope of the Sarcoidosis Market Report
• Coverage- 7MM
• Study Period- 2019-2032
• Sarcoidosis Companies- Pfizer, United Therapeutics, Xentria, Inc., aTyr Pharma, Inc., Kyorin Pharmaceutical Co., Ltd, Novartis, Kinevant Sciences GmbH, Foresee Pharmaceuticals, AI Therapeutics, Molecure, aTyr Pharma, and others
• Sarcoidosis Therapies- Abrocitinib, Inhaled Treprostinil, XTMAB-16, Efzofitimod, CMK389, Namilumab, FP-020, LAM001, OATD-01, and others.
• Sarcoidosis Market Dynamics: Sarcoidosis Market Drivers and Barriers
• Sarcoidosis Market Access and Reimbursement, Unmet Needs and Future Perspectives
Discover more about Sarcoidosis Drugs in development @ Sarcoidosis Clinical Trials Assessment - - https://www.delveinsight.com/sample-request/sarcoidosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Table of Content
1. Key Insights
2. Executive Summary of Sarcoidosis
3. Competitive Intelligence Analysis for Sarcoidosis
4. Sarcoidosis: Market Overview at a Glance
5. Sarcoidosis: Disease Background and Overview
6. Patient Journey
7. Sarcoidosis Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Sarcoidosis Unmet Needs
10. Key Endpoints of Sarcoidosis Treatment
11. Sarcoidosis Marketed Products
12. Sarcoidosis Emerging Therapies
13. Sarcoidosis: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Sarcoidosis
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Related Reports:
• Trigeminal Neuralgia Market Size: https://www.delveinsight.com/report-store/chronic-pain-market
• Ventricular Fibrillation Market: https://www.delveinsight.com/report-store/electrophysiology-devices-market
• Adamantinoma Market: https://www.delveinsight.com/blog/bone-cancer-treatment-market
• Healthcare Subscription Models: https://www.delveinsight.com/blog/subscription-model-in-healthcare
• Healthcare Competitive Benchmarking: https://www.delveinsight.com/consulting/competitive-benchmarking-services
• Capnography Device Market: https://www.delveinsight.com/report-store/capnography-devices-market
• Benefits Of Robotics In Healthcare: https://www.delveinsight.com/blog/robotics-in-healthcare
• Wound Irrigation Systems Market: https://www.delveinsight.com/report-store/wound-irrigation-systems-market?utm_source=Medgadget&utm_medium=pressrelease&utm_campaign=kupr
• Pulse Oximeter Market: https://www.delveinsight.com/report-store/pulse-oximeters-market
• Gaucher Disease Market: https://www.delveinsight.com/report-store/gauchers-disease-market
• Anti-cd274 Pd-l1 Antibody Pipeline: https://www.delveinsight.com/report-store/pd-1-and-pd-l1-inhibitors-competitive-landscape
• Apheresis Market: https://www.delveinsight.com/report-store/apheresis-market
• Atherectomy Devices Market: https://www.delveinsight.com/report-store/atherectomy-devices-market
• Hearing Implants Market: https://www.delveinsight.com/report-store/hearing-implants-market
• Menopause Market: https://www.delveinsight.com/report-store/menopause-market
• Ophthalmic Imaging Equipment Market: https://www.delveinsight.com/report-store/ophthalmic-imaging-equipment-market
• Aortic Aneurysm Stent Grafts Market: https://www.delveinsight.com/report-store/aortic-aneurysm-stent-grafts-market
• Blood Glucose Monitoring Systems Market: https://www.delveinsight.com/report-store/blood-glucose-monitoring-systems-market
• Chronic Lymphocytic Leukemia Cll Market: https://www.delveinsight.com/report-store/chronic-lymphocytic-leukemia-cll-market
• Healthcare Due Diligence Services: https://www.delveinsight.com/consulting/due-diligence-services
• Pressure Ulcers Market: https://www.delveinsight.com/report-store/pressure-ulcers-market
• Pulse Oximeters Market: https://www.delveinsight.com/report-store/pulse-oximeters-market
• Diabetic Foot Ulcers Dfus Market: https://www.delveinsight.com/report-store/diabetic-foot-ulcers-dfus-market
• Energy Based Aesthetic Devices Market: https://www.delveinsight.com/report-store/energy-based-aesthetic-devices-market
• Hepatitis B Virus Market: https://www.delveinsight.com/report-store/chronic-hepatitis-b-virus-market
• Minimal Residual Disease Market: https://www.delveinsight.com/report-store/minimal-residual-disease-market
• Vertigo Market: https://www.delveinsight.com/report-store/vertigo-market
• Chronic Hepatitis B Virus Market: https://www.delveinsight.com/report-store/chronic-hepatitis-b-virus-market
• Neuroprosthetics Market: https://www.delveinsight.com/blog/neuroprosthetics-market-analysis
• Non Alcoholic Fatty Liver Disease Nafld Market: https://www.delveinsight.com/report-store/non-alcoholic-fatty-liver-disease-nafld-market
• Palmar Hyperhidrosis Market: https://www.delveinsight.com/report-store/palmar-hyperhidrosis-market
• Acute Pain Market: https://www.delveinsight.com/report-store/acute-pain-market
• Automated External Defibrillators Market: https://www.delveinsight.com/report-store/external-defibrillators-market
• Dysthymia Market: https://www.delveinsight.com/report-store/persistent-depressive-disorder-market?utm_source=globenewswire&utm_medium=pressrelease&utm_campaign=spr
• Interbody Cages Market: https://www.delveinsight.com/report-store/interbody-cages-market
• Osteoarthritis Market: https://www.delveinsight.com/report-store/knee-osteoarthritis-market
• Palmar Hyperhidrosis Market Size: https://www.delveinsight.com/report-store/palmar-hyperhidrosis-market
• Wet-age Related Macular Degeneration Market: https://www.delveinsight.com/report-store/wet-age-related-macular-degeneration-wet-amd-market
• X Linked Hypophosphatemia Market: https://www.delveinsight.com/report-store/x-linked-hypophosphatemia-market
• Absssi Market Size: https://www.delveinsight.com/report-store/acute-bacterial-skin-and-skin-structure-infections-market
• Age-related Macular Degeneration Market: https://www.delveinsight.com/report-store/age-related-macular-degeneration-amd-market
• Androgenetic Alopecia Market: https://www.delveinsight.com/report-store/androgenetic-alopecia-market
• Arthroscopy Devices Market: https://www.delveinsight.com/report-store/arthroscopy-devices-market
• Artificial Kidney Market: https://www.delveinsight.com/report-store/artificial-kidney-market
• Carpal Tunnel Syndrome Market: https://www.delveinsight.com/report-store/carpal-tunnel-syndrome-market
• Central Pain Syndrome Market: https://www.delveinsight.com/report-store/central-pain-syndrome-market
• Cough Assisted Device Market: https://www.delveinsight.com/report-store/cough-assist-devices-market
• Duchenne Muscular Dystrophy Market: https://www.delveinsight.com/blog/duchenne-muscular-dystrophy-market
• Hearing Aid Devices Market: https://www.delveinsight.com/report-store/audiology-devices-market
• Neurovascular Devices Market: https://www.delveinsight.com/report-store/neurovascular-devices-interventional-neurology-market
• Prefilled Syringes Market: https://www.delveinsight.com/report-store/prefilled-syringes-market
• Xerostomia Market: https://www.delveinsight.com/report-store/xerostomia-market
Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Sarcoidosis Treatment Market 2032: EMA, PDMA, FDA Approval, Clinical Trials, Medication, NICE Approval, Prevalence, Revenue, Statistics and Companies by DelveInsight here
News-ID: 3983546 • Views: …
More Releases from DelveInsight Business Research
Spasticity Clinical Pipeline 2025: A Comprehensive Review of 12+ Emerging Therap …
According to DelveInsight's latest analysis, the global Spasticity pipeline features more than 10 active pharmaceutical companies that are advancing over 12 investigational therapies. The report offers a detailed evaluation of clinical trials, mechanisms of action, therapeutic approaches, routes of administration, and major developmental activities shaping the Spasticity treatment landscape.
DelveInsight's report, "Spasticity Pipeline Insight, 2025," delivers an extensive overview of the current clinical development environment and the future outlook for the…
Real-World Evidence Solution Market is set to grow at a 8.07% CAGR, reaching USD …
According to DelveInsight, the real-world evidence (RWE) solutions market is expanding rapidly, primarily due to the increasing global burden of chronic diseases and the growing need to improve healthcare outcomes. In addition, advancements in big data analytics, artificial intelligence, and machine learning are enhancing the ability to efficiently process and interpret large-scale real-world datasets. The rising adoption of RWE solutions by pharmaceutical and biotechnology companies - to support drug development,…
Spinal Implants Market is set to grow at a 5.50% CAGR, reaching USD 21.9 billion …
According to DelveInsight's assessment, the rising burden of spinal disorders particularly within the growing elderly population - continues to significantly increase the demand for surgical correction procedures. Alongside this, the surge in sports-related injuries and trauma cases is accelerating the need for advanced implantable spinal solutions. There is also a notable shift toward non-fusion and motion-preserving devices that support spinal flexibility and enhance patient outcomes, especially for younger and more…
Vascular Stents Market is set to grow at a 6.65% CAGR, reaching USD 18.28 billio …
According to DelveInsight's assessment, the rising global burden of cancer is significantly increasing the demand for advanced treatment approaches such as tumor ablation. Minimally invasive ablation techniques are gaining strong traction due to their advantages, including faster recovery times, lower complication risks, and reduced costs compared with traditional surgical procedures. At the same time, continuous improvements in ablation technologies - particularly in radiofrequency, microwave, and cryoablation systems - have enhanced…
More Releases for Sarcoidosis
Emerging Trends to Reshape the Sarcoidosis Drug Market: Innovation In Sarcoidosi …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Sarcoidosis Drug Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market for sarcoidosis drugs has experienced substantial growth in the recent past. The market size is predicted to escalate from $7.43 billion in 2024 to $7.88 billion in 2025, exhibiting a compound annual growth…
Pulmonary Sarcoidosis Market to Set Phenomenal Growth From 2025 to 2034
Introduction
Pulmonary sarcoidosis is a chronic inflammatory disease that primarily affects the lungs but can also involve other organs such as the heart, liver, and eyes. It is characterized by the formation of granulomas, which can impair organ function. Though the exact cause remains unclear, the disease is believed to result from an abnormal immune response. Pulmonary sarcoidosis often presents as a progressive condition, leading to symptoms such as shortness of…
Sarcoidosis Market Massive Growth opportunity Ahead
Introduction
Sarcoidosis is a rare, multisystem inflammatory disease characterized by the formation of granulomas in organs such as the lungs, skin, eyes, and lymph nodes. Although its exact cause remains unknown, it is believed to be linked to immune system overactivation, genetic predisposition, and environmental triggers. While many cases resolve spontaneously, chronic sarcoidosis can cause severe complications, particularly in pulmonary and cardiac systems.
The global sarcoidosis market is gaining attention as healthcare…
Pulmonary Sarcoidosis Market Dynamics Indicate Upward Trajectory Through 2032, R …
The Pulmonary Sarcoidosis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Pulmonary Sarcoidosis pipeline products will significantly revolutionize the Pulmonary Sarcoidosis market dynamics.
DelveInsight's "Pulmonary Sarcoidosis Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Pulmonary Sarcoidosis, historical and forecasted epidemiology as well as the Pulmonary Sarcoidosis market trends in the United…
Sarcoidosis Market Set to Eyewitness Substantial Growth by 2024-2031
The Latest research report on the Sarcoidosis Market 2024 provides a comprehensive analysis of the current market landscape, with forecasts extending to 2031. This study combines qualitative and quantitative insights to highlight significant market developments, challenges, competitive dynamics, and potential opportunities and trends shaping the Sarcoidosis Market. The report covers market size, recent trends, growth projections, market share, and development status. Additionally, it examines government policies, market dynamics, cost structures,…
Pulmonary Sarcoidosis Pipeline Therapeutics Assessment Report 2024 (Updated)
DelveInsight's, "Pulmonary Sarcoidosis Pipeline Insight 2024" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Pulmonary Sarcoidosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment options in the Pulmonary…
